How taking magnesium affects sleep and health in adults with poor sleep quality: a study with randomized blinding and placebo control

Effectiveness of magnesium supplementation on sleep quality and related health outcomes for adults with poor sleep quality: a randomized double-blind placebo-controlled crossover trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN70584524

Enrollment

Registered

2023-11-09

Start date

2023-03-03

Completion date

Unknown

Last updated

2023-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adults with nonclinical insomnia symptoms Mental and Behavioural Disorders

Interventions

For the 2 conditions (magnesium and placebo control) the procedures were identical except for the supplement taken (i.e., either magnesium or control). 1. Magnesium: Participants took

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults between the ages of 25 to 55 with nonclinical insomnia symptoms

Exclusion criteria

Exclusion criteria: 1. Severe insomnia (based on the Insomnia Severity Index (ISI = 22) or absence of insomnia (ISI < 8); 2. History of a disorder affecting sleep quality 3. Events that could cause severe stress within 2 weeks of baseline 4. Use of medication that could influence sleep patterns, within 1 month of baseline 5. Current use of hormone therapy 6. Binge drinking 7. Smoking 8. High caffeine intake 9. Work schedule that causes irregular sleep patterns 10. History of travel to a different time zone within 1 month of study 11. Low or high body mass index (BMI = 18 kg/m² or =30 kg/m²) 12. Pregnant, trying to conceive, or breastfeeding 13. Taking sleep supplements or medication 14. Unwilling to abstain from other magnesium product use for two weeks leading up to trial initiation and during the trial 15. Individuals deemed incompatible with the study protocol

Design outcomes

Primary

Measure	Time frame
Sleep measured by: 1. Questionnaires: 1.1. Insomnia Severity Index was measured at baseline and post each condition 1.2. Pittsburgh Sleep Quality Index (PSQI) was measured at baseline and post each condition 1.3. Berlin Questionnaire was measured at baseline and post each condition 1.4. Restorative Sleep Questionnaire was measured at baseline and post each condition 2. Objective wearable measure: Oura Ring which is a multisensory wearable device that quantifies night-time and daytime activity was measured daily	—

Measure

Time frame

Sleep measured by: 1. Questionnaires: 1.1. Insomnia Severity Index was measured at baseline and post each condition 1.2. Pittsburgh Sleep Quality Index (PSQI) was measured at baseline and post each condition 1.3. Berlin Questionnaire was measured at baseline and post each condition 1.4. Restorative Sleep Questionnaire was measured at baseline and post each condition 2. Objective wearable measure: Oura Ring which is a multisensory wearable device that quantifies night-time and daytime activity was measured daily

—

Secondary

Measure	Time frame
1. Profile of Mood States was measured at baseline and post each condition 2. Flinders Fatigue Scale was measured at baseline and post each condition 3. Perceived Stress Scale was measured at baseline and post each condition 4. Pain and Sleep Questionnaire Three-item Index was measured at baseline and post each condition 5. Trait Anxiety Inventory. was measured at baseline and post each condition 6. Adherence and adverse events: was measured daily via a questionnaire	—

Measure

Time frame

1. Profile of Mood States was measured at baseline and post each condition 2. Flinders Fatigue Scale was measured at baseline and post each condition 3. Perceived Stress Scale was measured at baseline and post each condition 4. Pain and Sleep Questionnaire Three-item Index was measured at baseline and post each condition 5. Trait Anxiety Inventory. was measured at baseline and post each condition 6. Adherence and adverse events: was measured daily via a questionnaire

—

Countries

United States of America

Contacts

Public ContactHeather Hausenblas

hhausenblas@wellnessdiscoverylabs.com+1 9048919746

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026